Company intelligence / Profile preview

Genenta Science

Milan*, Lombardy*, Italygenenta.com ↗

Ownership: Public · GNTA
Employees: ~14
Development stage: Phase 1

Overview

Genenta’s lead product, Temferon™, has completed a Phase 1 trial in newly diagnosed glioblastoma multiforme patients with unmethylated MGMT promoter, showing potential for reprogramming the tumor microenvironment and breaking immune tolerance. A Phase 1/2a study in metastatic renal cell carcinoma began in Q4 2024, including combination with immune checkpoint inhibitors. The approach is designed as a one-time monotherapy but may enhance efficacy when combined with other therapeutics[1].

Therapeutic areas: Oncology
Modalities: Hematopoietic stem cell gene therapyCell therapyGene-modified myeloid cells[1][3]
Industry: Biotech

Drug pipeline

1 asset

Temferon

Financials

Market cap: $19M
Total revenue: $0
Enterprise value: $-1.6M

Beyond the preview

Go deeper on Genenta Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genenta Science.

Explore the full profile